Foley Mark J

Average Profitability
21.46%
Insider Buys Quantity
3
Insider Buys Sum
$1.26M
Insider Sells Quantity
6
Insider Sells Sum
$7.29M

Insider Activity of Foley Mark J

According to the SEC Form 4 filings, Foley Mark J, being in a position of

  1. director at Glaukos Corporation,
    оver the last 12 months, has bought 0 shares, and sold 4560 shares for $423,487,
    over all time since 2024-02-23, has bought 0 shares, and sold 4560 shares for $423,487.

The largest purchase of all time was on 2017-11-07 and amounted to 20000 shares of Revance Therapeutics, Inc. for $539,168.

The largest sale of all time was on 2023-05-15 and amounted to 70447 shares of Revance Therapeutics, Inc. for $2.43M.

Biography of Foley Mark J

No biography is available at this moment.

2024-03-06PurchaseRevance Therapeutics, Inc.
RVNC
CEO
30,000
0.0377%
$6.98$209,400-30.68%
2024-02-23SaleGlaukos Corporation
GKOS
director
4,560
0.0097%
$92.87$423,487+26.71%
2023-08-03SaleRevance Therapeutics, Inc.
RVNC
CEO
26,279
0.0307%
$22.57$593,151-73.61%
2023-07-03SaleRevance Therapeutics, Inc.
RVNC
CEO
26,279
0.0322%
$24.94$655,333-72.17%
2023-06-09SaleRevance Therapeutics, Inc.
RVNC
CEO
31,279
0.0397%
$30.72$960,928-75.29%
2023-05-15SaleRevance Therapeutics, Inc.
RVNC
CEO
70,447
0.0886%
$34.55$2.43M-75.34%
2023-03-09SaleRevance Therapeutics, Inc.
RVNC
CEO
70,390
0.0885%
$31.59$2.22M-45.58%
2021-11-29PurchaseRevance Therapeutics, Inc.
RVNC
CEO
40,000
0.0613%
$12.90$515,924+33.51%
2017-11-07PurchaseRevance Therapeutics, Inc.
RVNC
director
20,000
0.0637%
$26.96$539,168+9.42%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.